Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC

Launched by FUDAN UNIVERSITY · Jun 2, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how to predict the outcomes for patients with colorectal cancer (CRC) by looking at special cells called circulating tumor cells (CTCs). These cells can be found in the blood of patients with CRC, and the trial will examine their shape and specific markers to help build a model that can predict how well patients might do after surgery. The researchers will compare the information gathered before and after surgery with the patients' survival data to see if the model works.

To join this study, participants need to be between 18 and 80 years old and have a confirmed diagnosis of colorectal cancer that can be surgically removed. They should not have received any pre-surgery treatments like chemotherapy or radiation, and they should not have other active cancers. Once enrolled, participants will provide consent and will have their blood tested to identify and analyze the CTCs. This study is currently not recruiting participants yet, but it aims to help improve the understanding of colorectal cancer prognosis for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-80 years;
• • Histologically proven colorectal carcinoma (TNM stage I-IV)
• • R0 resection is possible according to preoperative evaluation
• • Written informed consent for participation in the trial.
• Exclusion Criteria:
• • Primary tumor or metastases not able to be removed radically
• • Receiving any preoperative treatment (Including chemotherapy, radiotherapy and target therapy)
• • Have other malignant tumors meanwhile
• • Other previous malignancy within 5 years